Supernus Pharma (SUPN) Misses Q1 EPS by 38c, reaffirms guidance

Supernus Pharma (NASDAQ: SUPN) reported Q1 EPS of $0.00, $0.38 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $143.6 million versus the consensus estimate of $145.94 million.

GUIDANCE:

Supernus Pharma sees FY2024 revenue of $580-620 million, versus the consensus of $601.46 million. Operating loss guidance of $(30) million to $0 million, and adjusted operating earnings (non-GAAP) guidance of $80 million to $110 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
• Ionis Pharmaceuticals (IONS) reaffirms guidance
• Morgan Stanley downgrades Chinese luxury auto dealers on weak demand